en تخصصي Special پژوهشي Research <br> &nbsp;<span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Objective</span></span></span></b><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">:</span></span></span></b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""> Bullous pemphigoid is a rare autoimmune skin disorder characterized by blistering, urticarial lesions, which are sometimes associated with adverse drug reactions.</span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Vildagliptin is an oral anti-diabetic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme.</span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Materials and Methods</span></span></span></b><b><span dir="RTL" lang="FA" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">:</span></span></span></b><b> </b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">A 75-year-old female with a known case of type 2 Diabetes Mellitus, hypertension, and hypothyroidism for the last 10 years presented with pruriginous tense bullous skin lesions over her both palms and soles. There was no mucosal involvement. Further interrogation revealed that she started taking Vildagliptin 5 days ago which was prescribed due to high levels of post-prandial blood sugar level despite already intake of Glimepiride-4 mg and Metformin-3 gm.</span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Results</span></span></span></b><b><span dir="RTL" lang="FA" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">:</span></span></span></b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""> Vildagliptin was immediately advised to be stopped. She was treated with antihistamines, steroids, and conservative management which led to remission of the blisters.</span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Conclusion:</span></span></span></b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""> Vildagliptin is the probable causative drug for developing bullous pemphigoid skin lesion which shows temporal association in this case as other concomitant drugs has no direct correlation. Therefore physicians must be aware of this rare life-threatening side effect of this medicine and advice patients to visit the hospital even the slightest cutaneous manifestation. Bullous pemphigoid can result in fatal life-threatening conditions if not treated early.</span></span></span><span dir="RTL" lang="AR-SA" style="font-size:10.5pt"><span style="line-height:115%"><span style="font-family:"Times New Roman","serif""></span></span></span></span></span></span></span><br> &nbsp; Antibody engineering, Anti-VEGF-A, Bioinformatic, Binding affinity, Ranibizumab 122 126 http://ijdo.ssu.ac.ir/browse.php?a_code=A-10-30-413&slc_lang=en&sid=1 Debanjan Roy 0009-0002-4460-5100 No Post-Graduate Trainee, Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, India. Gunjan Gayen 0009-0004-7973-410X No Post-Graduate Trainee, Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, India. Sabnam Ara Begum 0009-0007-9305-2422 No Associate Professor, Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, India. Sandip Ghosh 0009-0005-4831-5145 No Principal, R.G. Kar Medical College and Hospital, Kolkata, India. Sucheto Talukder 0009-0004-2931-3219 No Undergraduate Student (M.B.B.S), R.G. Kar Medical College and Hospital, Kolkata, India. Arisha Sarkar 0009-0003-8427-389X No Undergraduate Student (M.B.B.S), R.G. Kar Medical College and Hospital, Kolkata, India. Shritama Aich 0009-0008-7679-0113 Yes Multidisciplinary Research Unit, R.G. Kar Medical College and Hospital, Kolkata, India.